Durata Therapeutics (DRTX) Sees IPO Price of $11 - $13/Share
Get Alerts DRTX Hot Sheet
Join SI Premium – FREE
Durata Therapeutics (Nasdaq: DRTX) filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The Company plans to offer 6,250,000 shares of Common Stock and sees an offering price of $11 to $13 per share. Durata plans to list on the Nasdaq Global Market under the ticker, "DRTX."
The offering is being made through BofA Merrill Lynch, Credit Suisse, RBC Capital Markets, and Wedbush PacGrow Life Sciences.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
The offering is being made through BofA Merrill Lynch, Credit Suisse, RBC Capital Markets, and Wedbush PacGrow Life Sciences.
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Nutriband (NTRB) Announces 2.1M Share Offering at $4/sh
- Vaxxinity, Inc (VAXX) to Voluntarily Delist
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!